Hydroxyamfetamine
Adrenergic Receptor Agonist
Also known as: hydroxyamfetamine hydrobromide, hydroxyamphetamide, hydroxyamphetamin, hydroxyamphetamine, hydroxyamphetamine hydrobromide, methyltyramine, oxamphetamine, para-Hydroxyamphetamine, paredrine
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Hydroxyamfetamine is an ofm drug in the Adrenergic Receptor Agonist class catalogued in DrugCentral. It was first approved by the FDA in 1969. Its mechanism of action is classified as Adrenergic Agonists. DrugCentral lists 3 molecular targets, including Taar1, TAAR1 and BACE1. Recorded indications include Dilated pupil.
- Approval status: ofm (first approved 1969 by the FDA).
- Drug class: Adrenergic Receptor Agonist.
- Mechanism of action: Adrenergic Agonists.
- Molecular targets: Taar1, TAAR1 and BACE1 (3 listed in DrugCentral).
- Indications: Dilated pupil.
- Molecular formula: C9H13NO; molecular weight 151.21 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Dilated pupil
Contraindications (8)
- Angle-closure glaucoma
- Conduction disorder of the heart
- Diabetes mellitus
- Hypertensive disorder
- Hyperthyroidism
- Myocardial ischemia
- Ocular hypertension
- Open-angle glaucoma
Mechanism & targets
| Mechanism of action (MoA) | Adrenergic Agonists |
|---|---|
| Established pharmacologic class | Adrenergic Receptor Agonist |
Molecular targets (3)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Trace amine-associated receptor 1 | Taar1 | unknown | EC50 7.30 |
| Trace amine-associated receptor 1 | TAAR1 | agonist | EC50 5.53 |
| Beta-secretase 1 | BACE1 | unknown | Kd 3.10 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1969-07-16 | FDA | — | PHARMICS |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Hydroxyamfetamine is on its molecule page.
| Molecular formula | C9H13NO |
|---|---|
| Molecular weight | 151.21 g/mol |
| CAS number | — |
| InChIKey | GIKNHHRFLCDOEU-UHFFFAOYSA-N |
| PubChem CID | 3651 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Hydroxyamfetamine used for?
DrugCentral lists the following indications for Hydroxyamfetamine: Dilated pupil.
How does Hydroxyamfetamine work?
Hydroxyamfetamine is classified as Adrenergic Agonists; its molecular targets in DrugCentral include Taar1, TAAR1 (agonist) and BACE1.
When was Hydroxyamfetamine first approved?
Hydroxyamfetamine was first approved by the FDA in 1969.
What drug class does Hydroxyamfetamine belong to?
Hydroxyamfetamine is in the Adrenergic Receptor Agonist class.
What is the chemical formula of Hydroxyamfetamine?
Hydroxyamfetamine has the molecular formula C9H13NO and a molecular weight of 151.21 g/mol.
Browse: all drugs starting with H · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 1394 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1200705 — compound record and bioactivity
- PubChem CID 3651 — chemical identifiers
- DrugBank DB09352 — drug record
- FDA UNII 59IG47SZ0E — substance identity
- DailyMed: FDA labels for Hydroxyamfetamine — current prescribing information (label search)
- UniProt Q96RJ0 (TAAR1) — target protein
- UniProt P56817 (BACE1) — target protein
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.